[{"id":"4bf912ed-2f96-4d90-aef7-e45022410420","acronym":"","url":"https://clinicaltrials.gov/study/NCT00186888","created_at":"2025-07-19T13:43:51.175Z","updated_at":"2025-07-19T13:43:51.175Z","phase":"Phase 3","brief_title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","source_id_and_acronym":"NCT00186888","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" ABCG2 • CYP3A4","pipe":"","alterations":" ","tags":["ABCG2 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 04/07/2005","start_date":" 04/07/2005","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/12/2024","study_completion_date":" 11/12/2024","last_update_posted":"2025-04-15"},{"id":"e32a87b6-7193-4a78-a806-d31027dab74d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02428101","created_at":"2021-01-18T11:36:57.221Z","updated_at":"2024-07-02T16:35:27.965Z","phase":"","brief_title":"Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer","source_id_and_acronym":"NCT02428101","lead_sponsor":"Ain Shams University","biomarkers":" ABCG2","pipe":"","alterations":" ","tags":["ABCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 80","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-11-28"},{"id":"b00fc8ee-1191-428e-8093-c4351326248c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00898456","created_at":"2021-01-18T03:27:05.038Z","updated_at":"2024-07-02T16:35:39.792Z","phase":"","brief_title":"Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT00898456","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ABCB1 • ABCG2 • ABCC1","pipe":"","alterations":" ","tags":["ABCB1 • ABCG2 • ABCC1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 01/01/2100","primary_completion_date":" 01/01/2100","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-17"},{"id":"35b097a8-236d-4100-8ac8-8041f2ce0d05","acronym":"CORIST","url":"https://clinicaltrials.gov/study/NCT04247256","created_at":"2021-01-18T20:38:38.588Z","updated_at":"2024-07-02T16:36:16.327Z","phase":"Phase 2","brief_title":"A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI","source_id_and_acronym":"NCT04247256 - CORIST","lead_sponsor":"Scandion Oncology A/S","biomarkers":" KRAS • BRAF • ABCB1 • ABCG2 • UGT1A1 • SRPK1","pipe":" | ","alterations":" BRAF mutation • UGT1A1*1*1","tags":["KRAS • BRAF • ABCB1 • ABCG2 • UGT1A1 • SRPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • endovion (SCO-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/14/2020","start_date":" 05/14/2020","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-03-01"},{"id":"0fed4813-2327-42f4-8f7e-67b0a8ca6e06","acronym":"","url":"https://clinicaltrials.gov/study/NCT00679354","created_at":"2021-01-18T02:32:24.165Z","updated_at":"2024-07-02T16:37:08.366Z","phase":"Phase 2","brief_title":"Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy","source_id_and_acronym":"NCT00679354","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABCB1 • ABCG2","pipe":"","alterations":" ","tags":["ABCB1 • ABCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cilcane (cilengitide)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 07/01/2011","study_completion_date":" 07/01/2011","last_update_posted":"2018-08-01"},{"id":"e9be9adb-6de8-4dfa-a8e7-a588abff5a22","acronym":"","url":"https://clinicaltrials.gov/study/NCT01619618","created_at":"2021-01-18T06:56:29.266Z","updated_at":"2024-07-02T16:37:22.098Z","phase":"","brief_title":"Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial","source_id_and_acronym":"NCT01619618","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" KRAS • MET • RAS • ABCG2","pipe":"","alterations":" ","tags":["KRAS • MET • RAS • ABCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 183","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 07/01/2012","primary_completion_date":" 07/01/2012","study_txt":" Completion: 07/01/2012","study_completion_date":" 07/01/2012","last_update_posted":"2017-05-17"}]